Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment.
Paris, New York & Raleigh
- Tweets 1,091
- Following 235
- Followers 4,417
- Likes 211
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company.
To read the press release: cellectis.com/en/press/celle…
6
16,281
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update.
To read the press release: cellectis.com/en/press/celle…
3
525
@cellectis announces participation in upcoming investor conferences.
To read the press release: shorturl.at/lXN44
1
1
3
1,330
Cellectis Reports Financial Results for the Second Quarter 2026.
To read the press release:
cellectis.com/en/press/celle…
1
5
530
#Cellectis to Report Second Quarter Financial Results on August 6, 2026.
Full press release here: cellectis.com/en/press/celle…
6
736
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026.
Read the full press release here: cellectis.com/en/press/celle…
2
4
714
Today at #EHA2026, we shared final Ph1 results from BALLI-01, evaluating lasme-cel in patients with r/r B-ALL.
*100% ORR in the target Ph2 population (n=7)
*All responding patients proceeded to transplant
*Manageable safety profile
Full press release: cellectis.com/en/press/celle…
1
1
11
576
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL.
To read the press release: cellectis.com/en/press/celle…
1
3
11
2,061
#Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026.
Full press release here : cellectis.com/en/press/celle…
4
570
Cellectis announced two presentations at the @EHA_Hematology
>> Lasme-cel - Oral presentation | June 13
>> Eti-cel - Poster presentation | June 13
To read the press release: cellectis.com/en/press/celle…
4
10
2,525
Cellectis Reports Financial Results for the First Quarter 2026.
To read the press release: cellectis.com/en/press/celle…
5
365
Cellectis to report first quarter financial results on May 11, 2026.
to read the press release: cellectis.com/en/press/celle…
1
3
368
Cellectis presents epigenetic editing platform to turn genes off without altering DNA at the American Society of Gene & Cell Therapy annual meeting. #ASGCT2026
To read the press release: cellectis.com/en/press/celle…
2
5
352
@cellectis highlights today's interim Phase 2 data for cema-cel. Cema-cel was originally developed by Cellectis as UCART19, the first allogeneic CAR-T program we ever built. Congrats to the teams at Allogene & Servier!
To read the press release: lnkd.in/ethtUtXG
1
9
883
@cellectis Reports Full Year 2025 Financial Results and Provides a Business Update.
To read the press release: cellectis.com/en/press/celle…
2
3
544
📢 Save the Date: @cellectis will report Q4 & FY 2025 results on March 19
🗓️ Mar 19 (Post-market): Earnings Release
🗓️ Mar 20 (8:00AM ET / 1:00PM CET): Earnings Call
Join the webcast here: cellectis.com/en/press/celle…
#Biotech #Earnings
1
4
448
Et si le temps n'était plus l'ennemi du patient ? ⏳
Pour un cancer agressif, chaque minute est un combat. Un traitement "sur étagères" est : déjà produit, congelé et prêt à l'emploi >> l'interview d'@AChoulika sur @bfmbusiness à 08:48min: shorturl.at/kDpqS
3
7
676
From Paris 🇫🇷 to New York 🇺🇸 to Raleigh 🇺🇸: One Team, One Mission.🎗️
On #WorldCancerDay, we celebrate 26 years of pioneering gene editing. We aren’t just building treatments, we are engineering the end of the wait for patients.
Together, we edit the future.
ALT #WorldCancerDay - editing the future of cancer care
ALT #WorldCancerDay - editing the future of cancer care
ALT #WorldCancerDay - editing the future of cancer care
2
5
468
#Cellectis is moving into 2026: Transitioning to a late-stage #Allogeneic CAR-T company: 🎯 Lasme-cel: Pivotal Ph2 interim data (n=40) expected in Q4 2026.
🎯 Eti-cel: Ph1 full dataset (incl. IL-2) in Q4 2026.
Read more in the press release: cellectis.com/en/press/celle…
1
8
1,046
Meet us in San Francisco for #JPM2026
📍San Francisco | Jan 12-15th
📅 Schedule a meeting: investors@cellectis.com
Hope to see you there!
7
1,609